|Dr. Peter Salzmann M.B.A., M.D.||CEO & Director||1.09M||N/A||1967|
|Ms. Pamela Yanchik Connealy M.B.A.||Chief Financial Officer||544.84k||N/A||1962|
|Dr. Julia G. Butchko Ph.D.||Chief Devel. & Technology Officer||N/A||N/A||1971|
|Dr. Michael J. Elliott MBBS, Ph.D.||Chief Scientific Officer||N/A||N/A||1959|
|Dr. Alan Jacobs M.D.||VP & Head of Neurology Devel.||N/A||N/A||N/A|
|Dr. Ann M. Daus||VP & Head of Global Quality||N/A||N/A||N/A|
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.